# Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

> **NCT02539719** · PHASE1 · TERMINATED · sponsor: **Stemcentrx** · enrollment: 74 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** SC-003
- **DRUG:** SC-003 in combination with ABBV-181

## Key facts

- **NCT ID:** NCT02539719
- **Lead sponsor:** Stemcentrx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08
- **Primary completion:** 2019-01-02
- **Final completion:** 2019-01-02
- **Target enrollment:** 74 (ACTUAL)
- **Why stopped:** Strategic Considerations
- **Last updated:** 2019-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02539719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02539719, "Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02539719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*